In the treatment of myelofibrosis, there can be a brighter future.
In the treatment of myelofibrosis, there can be a brighter future.
In the treatment of myelofibrosis, there can be a brighter future.

Featured News and Events

December 11, 2017

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials. Read More

December 9-12, 2017

Learn about the data and development program we’ll be discussing at this year’s American Society of Hematology Annual Meeting. Read More

December 1, 2017

Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting. Read More

Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.

Impact Biomedicines is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers.

News & Events

December 11, 2017

Impact Biomedicines Presents Analysis at the 2017 ASH Annual Meeting Suggesting that Fedratinib Did Not Increase Wernicke Encephalopathy Risk in Phase 2 and 3 Myelofibrosis Clinical Trials. Read More

December 9-12, 2017

Learn about the data and development program we’ll be discussing at this year’s American Society of Hematology Annual Meeting. Read More

December 1, 2017

Impact Biomedicines Closes First Tranche of Oberland Capital Financing Following FDA Meeting. Read More